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Summary
Accumulation of macrophage foam cells in atherosclerotic blood vessel intima is a critical component of atherogenesis
mediated by scavenger receptor-dependent internalization of oxidized LDL. We demonstrated by coimmunoprecipitation
and pull-down assays that the macrophage scavenger receptor CD36 associates with a signaling complex containing Lyn
and MEKK2. The MAP kinases JNK1 and JNK2 were specifically phosphorylated in macrophages exposed to oxLDL. Using
cells isolated from SRA, TLR2, or CD36 null mice, and phospholipid ligands specific for either SRA or CD36, we showed that
JNK activation was mediated by CD36. Both foam cell formation and activation of JNK2 in hyperlipidemic mice were dimin-
ished in the absence of CD36. Furthermore, inhibition of Src or JNK blocked oxLDL uptake and inhibited foam cell formation
in vitro and in vivo. These findings show that a specific CD36-dependent signaling pathway initiated by oxLDL is necessary
for foam cell formation and identify potential targets for antiatherosclerosis therapy.Introduction
The formation and progression of atherosclerotic lesions is
a highly complex inflammatory process that results from interac-
tion of blood components, including monocytes, T cells, and li-
poproteins with cellular components of the arterial wall (Glass
andWitztum, 2001; Lusis, 2000; Libby, 2002). During atherogen-
esis, lipid-laden macrophages, known as foam cells, accumu-
late within the arterial neointima and become amajor contributor
to plaque. A critical step in foam cell formation is recognition and
internalization of oxLDL particles by specific macrophage scav-
enger receptors, including CD36 and scavenger receptor A
(SRA) (Platt and Gordon, 2001; Silverstein and Febbraio,
2000). Combined inhibition of these two receptors blocks hu-
man and murine foam cell formation in vitro (Kunjathoor et al.,
2002), and genetic deletion of either SRA or CD36 slows lesion
development in atherogenic apoE null mice (Suzuki et al., 1997;
Febbraio et al., 2000). Although the ligands and receptors that
mediate interaction of modified LDL particles withmacrophages
have been well defined, the intracellular processes that regulate
internalization and trafficking of lipids from oxLDL remain poorly
understood. Our lab has shown that CD36 accounts for a large
proportion of oxLDL uptake by macrophages (Febbraio et al.,
2000), especially when LDL is oxidized by leukocyte myeloper-
oxidase-generated reactive nitrogen species (Podrez et al.,
2000a), an oxidizing system shown to be highly relevant to the
atherosclerotic process (Podrez et al., 2000b, 2002). Since
CD36 has also been shown to mediate internalization signals
in macrophages, microglial cells, and retinal pigment epithelial
cells exposed to apoptotic cells, fibrillar amyloid, photoreceptor
outer segments, and staphylococcus (Febbraio et al., 2001; Fin-
nemann and Silverstein, 2001; Fadok et al., 1998; Hoebe et al.,
2005), and since CD36 has been shown to transduce signals
that regulate apoptotic and inflammatory responses in endothe-CELL METABOLISM 4, 211–221, SEPTEMBER 2006 ª2006 ELSEVIERlial cells and macrophages (Moore et al., 2002; Medeiros et al.,
2004; Jimenez et al., 2000; Janabi et al., 2000; Bamberger et al.,
2003; Hoebe et al., 2005; Stuart et al., 2005), we hypothesized
that a CD36 triggered signaling cascade in macrophages may
be involved in foam cell formation. Previous studies have impli-
cated nonreceptor tyrosine kinases of the src family and serine/
threonine kinases of the mitogen activated protein (MAP) kinase
family in CD36 signal transduction. For example, fyn kinase and
p38 MAPK were shown to be necessary for CD36-mediated en-
dothelial cell antiangiogenic responses to thromobospondin-1
(Jimenez et al., 2000); and fyn, lyn, and syk tyrosine kinases
and pERK and p44/42 MAP kinases have been implicated in
CD36-dependent THP-1 and microglial cell inflammatory re-
sponses to fibrillar amyloid (Moore et al., 2002; Bamberger
et al., 2003). In this manuscript, we report that exposing peri-
toneal macrophages from wild-type (WT) but not CD36 null
(CD362/2) mice to oxLDL led to activation of the MAP kinases
c-Jun N-terminal kinase (JNK)-1 and -2 and that pharmaco-
logic blockade of JNK or Src-family kinases inhibited CD36-
dependent foam cell formation in vitro and in vivo. In addition,
we showed a direct physical association in monocytic cells be-
tween the intracytoplasmic carboxy-terminal domain of CD36
and a signaling complex containing lyn kinase and MEKK2, an
upstream MAP kinase.
Results
OxLDL induced CD36-dependent activation of JNK
in macrophages
We investigated the role of CD36 in activation of specific MAP
kinase family members by oxLDL in murine peritoneal macro-
phages, comparing cells from WT and CD362/2 mice. Cells
were treated with 50 mg/ml oxLDL and the phosphorylation state
of MAP kinase family members determined by immunoblotINC. DOI 10.1016/j.cmet.2006.06.007 211
A R T I C L EFigure 1. CD36-dependent phosphorylation of macrophage JNK by oxidized lipoproteins and phospholipids
A) Immunoblot analysis of MAP kinases ERK, p38, and JNK in WT and CD362/2 mouse peritoneal macrophages treated with 50 mg/ml copper oxidized LDL (oxLDL) for
times indicated. The prefix ‘‘p’’ denotes blots probed with antibodies specific for phosphorylated forms of the proteins, while the corresponding unmarked rows are blots
using antibodies that recognize all forms to indicate total protein loaded.
B) Immunoblot analysis of phosphorylated JNK (p-JNK) frommacrophages exposed to oxLDL at different concentrations for 30min. Themembrane was then stripped and
reprobed with anti-JNK antibody to indicate total JNK loaded.
C)Macrophages fromWT (dark bars), SRA2/2 (hatched bars), or CD362/2 (clear bars) mice were treated with indicated ligands at 50 mg/ml for 30 min and assayed for JNK
activation by immunoblot. Data are graphed as the fold change in phosphorylation compared to untreated cells.
D) 50 mg/ml PAPC oxidized with the MPO system in the presence (+NO2) or absence (2NO2) of nitrite was exposed to macrophages from WT (squares) or CD36
2/2
(triangles) mice and phosphorylation of JNK assayed by immunoblot. Data are plotted as percent maximal response.
E) Immunoblot showing activation of JNK1 and JNK2 by +NO2LDL in macrophages fromWT, SRA
2/2, and CD362/2mice. Expression of total JNK1 and JNK2 is shown as
loading control.analysis. Figure 1A shows that Erk1/Erk2 and p38 became
phosphorylated transiently in both cell types, peaking at 5–15
min and returning to baseline by 30–60 min. Similarly, there
was no difference in phosphorylation of Erk5 in macrophages
from WT and CD362/2 mice (data not shown). In contrast to
the behavior of ERK and p38, JNK was phosphorylated only in
WT cells, not in CD362/2 cells. Phosphorylation peaked at
30 min and was sustained for over 60 min. CD36-dependent
phosphorylation of JNK was dose dependent, peaking at
50–100 mg/ml (Figure 1B). Phosphorylation of JNK was also
dependent on oxidation of the LDL; native LDL had no effect
at doses up to100 mg/ml (data not shown).
As further evidence for CD36 dependence of oxLDL-induced
JNK phosphorylation, we examined a form of oxLDL generated
by myeloperoxidase (MPO) in the presence of nitrite (+NO2LDL)
that we previously demonstrated to be a high-affinity ligand for
CD36 but that is not recognized by SRA (Podrez et al., 2000a).
We found that +NO2LDL-stimulated phosphorylation of JNK
similarly to copper oxidized LDL in cells from WT but not212CD362/2 mice (Figure 1C). Similarly, 1-palmitoyl-2-arachi-
donoyl-sn-glycero-3-phosphatidylcholine (PAPC) vesicles oxi-
dized by the same MPO/nitrite system (+NO2PAPC) when incu-
bated with macrophages also activated JNK in WT but not
CD362/2 cells (Figure 1D). Control LDL or PAPC preparations
exposed to all components of the MPO system except nitrite
(2NO2LDL and2NO2PAPC) hadminimal JNK stimulatory activ-
ity (Figures 1C and 1D), similar to results seen with native LDL
(data not shown).
To assess the role of the other major macrophage scavenger
receptor, SRA, in JNK activation we compared macrophages
fromSRA2/2micewith those fromWT and CD362/2mice, using
acLDL, a specific ligand for SRA that is not recognized by CD36
and +NO2LDL, a specific ligand for CD36 that is not recognized
by SRA. AcLDL did not activate JNK in any of the cells, while
+NO2LDL activated JNKs in both WT and SRA
2/2 cells, but
not in CD362/2 cells (Figure 1C). In these studies, we also exam-
ined specific members of the JNK family of MAP kinases, focus-
ing on the more widely expressed members JNK1 and JNK2CELL METABOLISM : SEPTEMBER 2006
CD36 signaling regulates foam cell formationFigure 2. CD36-dependent JNK2 phosphorylation
in vivo in macrophages transferred into hyperlipi-
demic mice
Thioglycollate-elicited peritoneal macrophages were
collected fromWT, CD362/2, or SRA2/2mice and in-
jected intraperitoneally into apoE2/2 recipient mice
maintained on Western or chow diets for 6 weeks.
Cells were recovered from the peritoneal cavity after
3 days and analyzed by immunoblot.
A)Bar graphs show themean6SD levels of phopho-
JNK for WT (n = 6), CD362/2 (n = 6), and SRA2/2
(n = 4) cells transferred into Western diet-fed recipi-
ents. A representative immunoblot with antibodies
to phospho-JNK1 and -2 (top) and total JNK1
and -2 (bottom) is shown below the graph.
B) Immunoblots with antibodies to phosphorylated
and total p38 and Erk1/2. RAW cells treated with
LPS were used as a positive control. ND indicates
normal chow diet-fed recipients.
C) Immunoblots with antibodies to phosphorylated
MKK4 and MKK3/6 show CD36-dependent activa-
tion of MKK4 in cells transferred into Western diet-
fed recipients.(JNK3 expression is restricted to brain, heart, and testis) (Davis,
2000). We found that both JNK1 and JNK2 in peritoneal mouse
macrophages were phosphorylated in response to treatment
with +NO2LDL but that activation of JNK2 was significantly
more predominant than JNK1 (Figure 1E).
To demonstrate that oxLDL treatment of macrophages
induced CD36-dependent JNK activity along with phosphoryla-
tion, we examined downstream targets of pJNK. oxLDL expo-
sure led to increased phosphorylation of the transcription factor
c-Jun and ATF2 in WT, but not CD362/2 cells (data not shown).
JNK2 was activated in vivo in hyperlipidemic mice
in a CD36 dependent manner
To evaluate the in vivo relevance of our observations, we utilized
a macrophage transfer assay described by Li et al. (2004). Peri-
toneal macrophages from donor mice (WT, CD362/2, or
SRA2/2) were transferred into the peritoneal cavities of proa-
therogenic apoE2/2 mice maintained on a ‘‘Western’’ diet for
six weeks to induce hyperlipidemia. Cells were removed 3
days later and analyzed. We hypothesized that the modified
LDL particles produced in these mice would activate JNK in
the donor macrophages, depending on the availability of
CD36. We found markedly higher levels of activation of JNK2
in WT and SRA2/2 macrophages compared to CD362/2 cells
(Figure 2A). These findings suggest that oxLDL-mediated acti-
vation of JNK2 occurs in vivo in the hyperlipidemic proathero-
genic mice and that is primarily dependent on CD36 expression.
We did not find any significant difference in activation of p38 and
Erk1/2 between WT and CD362/2 macrophages (Figure 2B),
demonstrating that the in vitro systems faithfully mimicked the
in vivo model. We also examined activation of upstream MAP
kinase kinases, including MKK4 and MKK3/6, in this model
and found higher activation of MKK4, not MKK3/6, in WT cells
compared to CD362/2 cells (Figure 2C), raising the possibilityCELL METABOLISM : SEPTEMBER 2006that activated MKK4 might be involved as an upstream MAPKK
in activation of JNK2.
The carboxy-terminal cytoplasmic tail of monocyte
CD36 interacts with a signaling complex containing
MEKK2 and lyn
To understand potential mechanisms by which CD36 activates
intracellular kinases, we sought to determine a role for the intra-
cellular domain(s) of CD36. Several laboratories have reported
that the Src-family nonreceptor protein tyrosine kinases fyn,
lyn, and yes coimmunoprecipitated with CD36 from human
platelet, endothelial cell, and monocytic cell line detergent
lysates (Medeiros et al., 2004; Huang et al., 1991; Bull et al.,
1994). The structural basis for this association is not known
and has been speculated to be due to CD36 interactions with
other membrane proteins, CD36 localization in caveolae-like
membrane microdomains, or direct interactions of CD36 intra-
cellular domains with kinases. Although CD36 has intracellular
domains at both its amino- and carboxy-terminal regions, we
hypothesized that the carboxy-terminal domain was the better
candidate to function as a binding site for intracellular signaling
proteins based on its homology to similar sites in CD4, CD8, and
other proteins (Shattil and Brugge, 1991; Shaw et al., 1990;
Turner et al., 1990) and because the amino-terminal domain is
extremely short. Using affinity chromatography with recombi-
nant GST/CD36 fusion proteins, we now report a direct associ-
ation between the CD36 carboxy-terminal domain and a signal-
ing complex in human monocytic cells. In pilot studies (data not
shown) using metabolically labeled THP-1 monocytic cells, we
identified nine bands by SDS-PAGE autoradiography ranging
from 40–120 kDa that bound to an immobilized GST-CD36 cyto-
plasmic tail fusion protein (P36I) but that did not bind to GST
alone or to a GST fusion protein containing a scrambled CD36
tail sequence (P36S). The recombinant CD36 cytoplasmic tail
peptide purified after cleavage from the fusion protein effectively213
A R T I C L EFigure 3. Interaction of the carboxy-terminal cyto-
plasmic tail of monocyte CD36 with a signaling com-
plex containing MEKK2 and lyn
A) GST or GST/CD36 cytoplasmic tail fusion protein
(P36I)-bound complexes from THP-1 cell lysates
were separated by SDS-PAGE and analyzed by
immunoblot with anti-MEKK2 antibody. The specific
MEKK2 band is shown with an arrow.
B) IP with anti-CD36 IgG or isotype control from
human platelet lysates. Complexes were analyzed
by immunoblot as in panel (A).
C) GST or GST/CD36 cytoplasmic tail fusion protein
(P36I)-bound complexes from THP-1 cell lysates
were assayed for tyrosine kinase activity in the pres-
ence of 32P-gATP. Labeled proteins were separated
by SDS-PAGE and visualized by autoradiography.
Arrows indicate proteins that became specifically
phosphorylated in P36I complexes.
D) GST or GST/CD36 cytoplasmic tail fusion protein
(P36I)-bound complexes from endothelial cell (EC) or
THP-1 cell lysates were analyzed by immunoblot
with anti-Lyn antibody. Cell extracts from EC and
THP-1 were used as negative and positive controls
respectively.
E) 293T cells were transiently transfected with CD36
and/or lyn cDNA. Cells were immunoprecipitated
using anti-CD36 antibody, and complexes were
probed for the presence of CD36 (top) and MEKK2
(bottom) by immunoblot analysis.
In all cases, blots or gels are representative of at least
three experiments.competed for seven of the nine proteins. To identify the P36I
binding proteins, similar studies were performed using a larger
number of unlabeled cells, and the eluted material was analyzed
by Western blot using antibodies to candidate antigens and by
2-D gel electrophoresis. Based on the size and pI of one of the
more prominent dots on the 2-D gels, we hypothesized that
one of the CD36 binding proteins was MEKK2, a component
of the MAP kinase pathway. Figure 3A shows a Western blot
confirming this; anti-MEKK2 IgG recognized a protein of the ap-
propriate MW in the material eluted from P36I, but not the GST
control. Further control studies showed that MEKK2 could be
eluted from P36I with recombinant CD36 cytoplasmic tail pep-
tide, but not the scrambled peptide, and that MEKK2 did not
bind to P36S. To validate the physical association of CD36
with MEKK2, we also demonstrated by immunoblot analysis
that MEKK2 was precipitated from human cells by an anti-
CD36 monoclonal antibody (Figure 3B).
To determine if the association of src-family kinases with
CD36 also involves the C-terminal cytoplasmic tail, we analyzed
the GST/P36I and control eluates by in vitro kinase assay and
Western blot with src-specific antibodies. Figure 3C shows
that the bound complex contained an active kinase withmultiple
substrates of 25–150 kDa (arrows). Using antibodies to specific
members of the src kinase family, we found that lyn was present
in the P36I eluate, but not the control GST eluate (Figure 3D,
right lanes). In contrast, eluates from a lysate made from a trans-
formed humanmicrovascular endothelial cell line did not contain
lyn (Figure 3D, left lanes), but did contain fyn (data not shown),
suggesting that CD36 associates with different kinases in differ-
ent cell types.214Interestingly, when CD36 cDNA was transfected into 293T
cells and the cells immunoprecipitated with anti-CD36 IgG
(Figure 3E), MEKK2 was found in the precipitates only if lyn
cDNA was cotransfected, suggesting that the CD36-lyn interac-
tion may be necessary to recruit MEKK2 into the complex.
OxLDL treatment leads to activation and recruitment
of signaling molecules to CD36
To assess the effects of CD36 ligands on the cytoplasmic tail
signaling complex, murine macrophages were exposed to the
CD36-specific ligand +NO2LDL and analyzed by immunopre-
cipitation (IP)/Western blot. We found 2.5- to 3-fold more lyn
and MEKK2 in the anti-CD36 IP from +NO2LDL treated cells
compared to cells exposed to nonoxidized LDL (Figure 4A).
Anti-lyn IP of +NO2LDL-exposed macrophages were examined
by immunoblot with an anti-phosphotyrosine antibody revealing
an w3-fold increase in tyrosine phosphorylation in WT com-
pared to CD362/2 cells (Figure 4B). This increase was blocked
completely by coincubation with a src inhibitor AG1879. As an
additional validation of the cytoplasmic pull-down assays, we
also performed IP with anti-MEKK2 and analyzed the precipi-
tates by immunoblot with anti-lyn and anti-phosphotyrosine.
As shown in Figure 4C, +NO2LDL-treated WT macrophages
showed increased phosphorylation of MEKK2 and lyn in the
MEKK2 IP compared to CD362/2 cells. Together, these studies
show that lyn, MEKK2, and CD36 coprecipitated from macro-
phages with antibodies to either CD36 or MEKK2 and that the
amount of MEKK2 and lyn and the degree of their phosphoryla-
tion was increased by exposure of the cells to +NO2LDL.CELL METABOLISM : SEPTEMBER 2006
CD36 signaling regulates foam cell formationFigure 4. Coprecipitation of CD36, lyn, and MEKK2
from macrophages treated with +NO2LDL
A)WT and CD362/2macrophages were treated with
50 mg/ml +NO2LDL or control 2NO2LDL and CD36
immunoprecipitated with monoclonal anti-CD36.
Coprecipitated lyn (top blot) and MEKK2 (middle
blot) were detected by immunoblot using specific
monoclonal antibodies. The blot was stripped and
reprobed with anti-CD36 antibody (lower blot). No
CD36-immunoreactive band was detected in
CD362/2 sample. Total lyn and MEKK2 were quanti-
fied and expressed as fold-change relative to
CD362/2 lane.
B)WT and CD362/2macrophages were treated with
50 mg/ml +NO2LDL for 20 min, and then lyn was im-
munoprecipitated. Phosphorylation of Lyn was as-
sayed by immunoblot with an anti-phosphotyrosine
antibody (top blot). The blot was stripped and re-
probed with anti-lyn (lower blot). A lysate from WT
cells pretreated with the src kinase inhibitor
AG1879 was used as a control.
C)WT and CD362/2macrophages were treated with
50 mg/ml +NO2LDL for 20 min, and then MEKK2 was
immunoprecipitated. The precipates were then ana-
lyzed by immunoblot with antibodies to p-MEKK2,
p-lyn, and total lyn. Top blot shows increased phos-
phorylation of MEKK2 in WT compared to CD362/2
cells. Lower blot shows coprecipitation of lyn with
the anti-MEKK2 and middle blot shows increased
phosphorylation of lyn in the WT cells compared to
CD362/2 cells. Total whole-cell lysate (WCL) was
used as a control.Inhibition of JNK or Src pathways prevented oxLDL
uptake and foam cell formation in murine
peritoneal macrophages
Having shown that oxLDL induced CD36-dependent macro-
phage JNK activation as well as increased physical association
between CD36, lyn, and MEKK2, we next assessed the biolog-
ical role of this system in macrophage scavenging function. We
examined oxLDL uptake and foam cell formation in the presence
of specific pharmacologic inhibitors, using a quantitative assay
based on Oil Red O staining (Febbraio et al., 2000; Podrez et al.,
2000a). Figure 5A shows that inhibition of JNK activation by ei-
ther a small molecular weight chemical inhibitor, SP600125, or
an HIV-TAT-based peptide inhibitor, JNKi, led to up to 80%
reduction in foam cell formation in peritoneal macrophages
exposed to either oxLDL or +NO2LDL. Similar results were found
when cells were treated with a broadly active Src family kinase
inhibitor, AG1879 (Figure 5B). Inhibition of Erk1/2 activity by
U0126, Jak by AG490, PI3Kinase by LY294002, or Protein Ki-
nase C by Go6983 had no significant effect on foam cell forma-
tion, demonstrating specificity. In these studies we found that
JNK inhibitors did not affect expression of PPARg or CD36
and that both JNK and Src inhibitors significantly decreased
the level of c-Jun phosphorylation in macrophages exposed to
+NO2LDL (data not shown). Interestingly, the src inhibitors did
not affect phosphorylation of JNK itself even though phosphor-
ylation of the downstream JNK target c-Jun was inhibited.
Recently, it was reported that CD36 functions as a coreceptor
with TLR2 to mediate recognition and internalization of phos-
pholipid components of the cell wall of staphylococcus bacteria.
Since TLR2 activation can result in activation of JNK, it was im-
portant to determine if CD36-dependent foamcell formation and
JNK activation involved TLR2. To address this possibility, peri-CELL METABOLISM : SEPTEMBER 2006toneal macrophages were obtained from TLR22/2 mice on the
same C57Bl background as CD362/2. We found that macro-
phages from TLR22/2 mice formed foam cells in response to
various forms of oxidized LDL (copper oxidized orMPO/NO2 ox-
idized) to the same extent asWT cells (Figure 5C).We also found
no difference in JNK phosphorylation in TLR22/2 null cells ex-
posed to the various forms of oxLDL compared to WT cells
(data not shown). Importantly, Western blots showed no differ-
ence in levels of CD36 expression in the TLR22/2 null cells com-
pared to WT. These studies show that CD36-dependent foam
cell formation does not require signaling through TLR2.
Macrophage scavenging function requires binding of ligand to
receptor followed by ligand internalization. To assess the role of
the CD36 signaling system in these processes, we exposed
cells to a fluorophore (DiI)-tagged form of +NO2LDL (DiI-
NO2LDL) and examined them by confocal fluorescence micros-
copy after short-term incubations at 4C tomeasure binding and
37C to measure internalization. No significant reduction in
binding of +NO2LDL was observed in JNK-inhibited cells, while
treatment with the src inhibitor caused a small inhibition of bind-
ing (Figure 6A). As reported previously (Febbraio et al., 2000), no
binding was seen to CD362/2 cells. Figure 6B, however, shows
that blockade of JNK kinase activation by SP600125 or src ki-
nase by AG1879 significantly inhibited +NO2LDL uptake by peri-
toneal macrophages. Similar results were seen with the JNKi
peptide (data not shown).
To show in vivo relevance for these observations, we exam-
ined foam cell formation in the macrophage transfer model de-
scribed above. Approximately 75% of WT or SRA2/2 donor
macrophages recovered from Western diet-fed apoE2/2 mice
stained strongly with Oil Red O, indicating foam cell formation,
compared to w25% of those from CD362/2 donors (Figure 7).215
A R T I C L EFigure 5. Inhibition of foam cell formation by pharmacologic inhibitors of JNK and Src-family kinases
A) Peritoneal macrophages were cultured for 48 hr in RPMI-1640 containing 10% FBS and were then treated with SP600125 (SP), U0126 (U), JNK1 peptide inhibitor (JNKi),
or control HIV-TAT peptide for 3 hr prior to incubation for an additional 18 hr with 50 mg/ml native LDL, copper oxidized LDL (ox LDL), or +NO2LDL. Cells were then fixed and
stained with Oil Red O to quantify foam cell formation. The bar graphs show the mean 6 SD of triplicate determinations.
B) Cells as in (A) were pretreated with inhibitors AG1879, AG490, LY294002 (LY), or Go6983 for 3 hr prior to incubation with modified LDL and staining with Oil Red O.
C) Thioglycollate-elicited peritoneal macrophages were collected from WT and TLR22/2mice and analyzed by Oil Red O staining to quantify the number of foam cells as
above. The corresponding bar graphs show the mean 6 SD for WT and TLR22/2 mice.WT cells transferred to apoE2/2micemaintained on a chow diet
did not form foam cells. These results correlate well with the
degree of JNK2 and MKK4 phosphorylation (Figure 2) and are
consistent with a model in which interaction of CD36 with spe-
cific oxidized phospholipids within oxLDL results in recruitment
of lyn and MEKK2 to the C-terminal cytoplasmic tail of CD36.
This then facilitates activation of these kinases and then down-
stream activation of JNK2 (presumably via MKK4) followed by
internalization of the bound ligands leading to formation of
foam cells.
Discussion
Macrophage foam cell formation is an essential yet incompletely
understood component of the atherogenic process. Critical
steps in foam cell formation include recognition and internaliza-
tion of modified lipoprotein particles, including oxLDL and
aggregated LDL, trapped in the arterial intima in response to in-
flammatory injury (Glass and Witztum, 2001; Lusis, 2000; Libby,
2002). This leads to accumulation of cholesterol and other lipids
within the macrophages, presumably due to insufficient activity
of lipid efflux and/or catabolic pathways. In this manuscript, we
have identified an intracellular signaling pathway triggered by
interaction of oxLDL with a specific scavenger receptor, CD36,216that is necessary for foam cell formation in vitro and in an in vivo
model involving cell transfer into hyperlipidemic mice. Using
a combination of specific pharmacologic inhibitors, scavenger
receptor null macrophages, and ligands with high degree of
specificity for CD36, we showed that the MAP kinases JNK-1
and JNK-2 were phosphorylated and activated in a CD36-
dependent manner by exposure of macrophages to oxLDL
and that blockade of JNK activation potently inhibited foam
cell formation. We also showed that the src-family kinase lyn
is part of this pathway by demonstrating an interaction between
the cytoplasmic domain of CD36 with lyn and MAPK pathway
upstream components and by showing that pharmacologic
blockade of src kinases also inhibited foam cell formation.
CD36-dependent signal transduction can proceed by at least
two pathways. By facilitating internalization of bioactive lipids
from oxLDL that activate nuclear receptors, such as PPARg,
CD36 can participate in the initiation of a transcriptional program
that includes upregulation of its own gene as well as those of
other critical genes involved in lipid metabolism (Tontonoz
et al., 1998; Nagy et al., 1998; Moore et al., 2001; Chinetti
et al., 2001; Li et al., 2004). Other data, however, suggest that
CD36 can function as traditional signal transduction receptor
initiating a signaling cascade conferred upon ligand binding
(Moore et al., 2002; Medeiros et al., 2004; Jimenez et al.,CELL METABOLISM : SEPTEMBER 2006
CD36 signaling regulates foam cell formationFigure 6. DiI-labeled +NO2LDL uptake, but not binding, is blocked in presence of JNK and Src family kinase inhibitors
Peritoneal macrophages from WT or CD362/2mice were pretreated with vehicle or inhibitors for 18 hr and then exposed to DiI-labeled +NO2LDL for 3 hr at 4
C (A) or for
5 min, 30 min, and 60 min at 37C (B) to assess binding and uptake of +NO2LDL respectively by confocal microscopy.2000; Janabi et al., 2000; Bamberger et al., 2003). For example,
the antiangiogenic activity of CD36 in microvascular endothelial
cells requires specific src and MAP kinases (Jimenez et al.,
2000) as do CD36-dependent generation of oxidative bursts in
macrophages and microglial cells (Moore et al., 2002; Medeiros
et al., 2004; Cho et al., 2005; El Khoury et al., 2003). It is interest-
ing that endothelial cell responses to CD36 are mediated by fyn
kinase and p38 MAP kinase, while the responses noted here
involve lyn and JNK, suggesting that different cell types may
respond differently to CD36 engagement, perhaps depending
on their predominant src-family member.
Work reported here sheds light on some of the molecular
mechanisms linking CD36, JNK, and src-family kinases. Others
have speculated that CD36 signal transduction may relate to in-
direct effects due to CD36 interactions with other transmem-
brane signaling receptors, such as CD9, CD47, b1 integrins,
SRA, and TLR2 (Miao et al., 2001; Thorne et al., 2000; Hoebe
et al., 2005; Stuart et al., 2005), or to CD36 membrane localiza-
tion in lipid rafts (Bamberger et al., 2003; Miao et al., 2001). We
now show, however, that CD36 signaling by oxLDL proceeds in
the absence of TLR2 and SRA and that the short 13 amino acidCELL METABOLISM : SEPTEMBER 2006carboxy terminal intracellular domain of CD36 was sufficient to
precipitate a multi-component signaling complex from mono-
cyte cell lysates. This domain contains a CXCX5K motif homol-
ogous to the sequence of the cytoplasmic domain in CD4 and
CD8 that serves as a docking site for signalingmolecules includ-
ing the src kinase lck (Shattil and Brugge, 1991; Shaw et al.,
1990; Turner et al., 1990). Others, however, have shown that
lyn and fyn do not bind with high affinity to this site. Interestingly,
Stuart et al. recently reported (2005) that Y468 and C464 in the
carboxy-terminal CD36 cytoplasmic domain were necessary
for TLR2/CD36-dependent internalization and inflammatory re-
sponses to phospholipids in staph bacteria. The precise role
of these residues in TLR2-independent CD36 functions, such
as foam cell formation, remains to be determined.
Our biochemical data suggest that the lyn-CD36 interaction is
necessary for recruitment of the MAP kinase component,
MEKK2 (Figure 3E). The observation that src inhibitors blocked
macrophage foam cell formation and c-Jun phosphorylation,
but did not inhibit JNK phosphorylation, is not easily explained.
Perhaps activation of lyn in a CD36-dependentmanner results in
transient recruitment of pJNK to a signaling complex that then217
A R T I C L EFigure 7. CD36-dependent in vivo foam cell forma-
tion in hyperlipidemic apoE2/2 mice
Thioglycollate-elicited peritoneal macrophages were
collected fromWT, CD362/2, or SRA2/2mice and in-
jected intraperitoneally into apoE2/2 recipient mice
maintained on Western or chow diets for 6 weeks.
Cells were recovered from the peritoneal cavity after
3 days and analyzed by Oil Red O staining to quantify
the number of foam cells. The corresponding bar
graphs show the mean 6 SD for WT (n = 6),
CD362/2 (n = 9), and SRA2/2 (n = 6) on Western
diet. As a control we have shown WT cells trans-
ferred into normal chow-fed animals (n = 3).allows oxLDL internalization. Blockade of lyn activity might then
alter intracellular localization of pJNK without changing its level,
and thereby inhibit foam cell formation. This is supported by
data (Figure 4) showing increased lyn phosphorylation in macro-
phages exposed to CD36 ligands and increased recruitment of
both p-lyn and MEKK2 to CD36 in response to oxLDL.
Our results, although based on in vitro experiments, are highly
relevant to recent in vivo findings. Oxidation of LDL by the mye-
loperoxidase system in vivo is supported by mass spectro-
scopic analysis of lipids in atheromatous plaque and by epide-
miologic data linking circulating MPO and nitrotyrosine levels
with atherosclerotic risk (Podrez et al., 2002; Ricci et al., 2004;
Yla-Herttuala et al., 1989; Palinski et al., 1989; Nicholls and
Hazen, 2005). Furthermore, lyn-deficient mice fed a high-fat
diet have been shown to have hyperlipidemia without increased
levels of atherosclerosis (Miki et al., 2001), JNK activity is upreg-
ulated in atheromas (Ricci et al., 2004; Metzler et al., 2000), and
macrophages closest to the lipid core of lesions express the
most CD36 (Nakata et al., 1999). Ricci et al. (2004) recently re-
ported studies showing decreased atherosclerosis in JNK2
null mice. They also showed decreased phosphorylation of
SRA in thesemice, suggesting a link between JNK2 andSRA ac-
tivity. Here, we showed that acLDL, a specific ligand for SRA,
did not activate JNK, while +NO2LDL, a specific ligand for
CD36, activated JNKs in wild-type but not CD36 null macro-
phages (Figure 1), suggesting that there may be ‘‘crosstalk’’
between CD36 and SRA pathways.
The precise role of JNK in foam cell formation remains to be
defined, but our data showing blockade of oxLDL uptake by218JNK inhibitors suggest that JNK is affecting a proximal step in
the process. These data are consistent with other studies from
our lab showing that CD36 signaling plays a role in internalization
of shedphotoreceptor outer segments by retinal pigment epithe-
lial cells (Finnemann and Silverstein, 2001). We thus propose
a model in which oxLDL binding to the extracellular domains of
CD36 leads to recruitment and activation of lyn kinase and the
upstreamMAP kinase MEKK2 at the carboxy terminal CD36 cy-
toplasmic tail. This interaction results in phosphorylation and ac-
tivation of JNK. Activation of JNK has been reported to regulate
numerous cellular processes via phosphorylation of substrates
involved in gene transcription, apoptosis and survival pathways,
metabolic pathways, cytoskeletal dynamics, and membrane
trafficking. Recent genome-wide siRNA based ‘‘forward ge-
netic’’ screens designed to define the role of kinases in basic cel-
lular processes have shown that kinases (including JNK) are re-
quired for clathrin- and raft-mediated endocytosis (Pelkmans
et al., 2005). It is thus likely that CD36-mediated activation of
JNK is required to deliver an internalization signal perhaps re-
lated to cytoskeletal or membrane dynamics. In addition, the
work of Ricci et al. (2004) suggests a role for JNK2 in macro-
phage cholesterol efflux to apoA1. Thus, CD36 signaling through
JNK may modulate foam cell formation via inhibition of both in-
flux and efflux of lipids. Although the studies in this manuscript
focus on foam cell formation, JNK signaling has been implicated
in many other processes of relevance to macrophage function,
including cytoskeletal dynamics, NFkB inflammatory signaling,
apoptosis, and insulin resistance. The role of oxLDL and CD36
in these events remains to be determined.CELL METABOLISM : SEPTEMBER 2006
CD36 signaling regulates foam cell formationExperimental procedures
Antibodies, cells, and other reagents
Antibodies to phosphorylated forms of Erk1/2, p38, JNK1/2, c-Jun, MKK4,
MKK3/6, and to native Erk1/2, p38, and Jnk1/2 were from Cell Signaling
Technology (Danvers, MA). Antibodies to phosphorylated Erk5, Erk5,
MEKK2, MKK4 and PPARg were from Santa Cruz Biotechnology (Danvers,
MA). Anti-Lyn was from BD-Transduction (Franklin Lakes, NJ), anti-actin
from Sigma (St. Louis, MO), and anti-HA from Berkeley Antibodies Co.
(Richmond, CA). Monoclonal anti-humanCD36was from Immunotech (West-
brook, ME), and polyclonal anti-murine CD36 was provided by Huy Ong, Uni-
versity of Montreal, Canada. Mouse monoclonal anti-mouse CD36 was
prepared as previously described (Finnemann and Silverstein, 2001) and
anti-p-tyrosine antibody was from Upstate Biotechnology (Lake Placid, NY).
AcLDL was purchased from Intracell (Issaquah, WA). PAPC was obtained
from Avanti polar lipids (Alabaster, Alabama) and small unilammelar lipo-
somes were prepared as previously described (Podrez et al., 2000a).
Oxidized lipoproteins and phospholipids and their nonoxidized controls
were prepared as described previously (Podrez et al., 2000a). DiI was from
Molecular probes (Eugene, OR) and U0126 from Promega (Madison, WI).
AG490, SP600125, LY294002, Go6983, AG1879, and JNKi (HIV-TAT-JNKi,
JNK inhibitory peptide) and HIV-TAT (control peptide) were purchased
from Calbiochem (La Jolla, CA). All chemicals were obtained from Sigma
(St. Louis, MO) unless otherwise indicated.
CD36 (Febbraio et al., 1999), SRA (Suzuki et al., 1997), and TLR2 null mice
(Takeuchi et al., 1999) were described previously. CD36 null mice were back-
crossed six times to C57Bl/6 and a background-matched WT control line
was used in all studies. Peritoneal macrophages were obtained by lavage
4 days after injection with thioglycollate and adherent cells maintained in cul-
ture as described (Febbraio et al., 2000). Cells from TLR22/2mice were gen-
erously provided by C. Harding (Case Western Reserve University). THP-1,
RAW, and 293T cells were obtained from ATCC. All cell culture reagents
were purchased from Life Technologies (Rockville, MD). Human platelets
were obtained from healthy, medication-free, volunteer donors following
IRB approved protocol. Platelets were separated from plasma by chroma-
tography of platelet-rich plasma on a sepharose 2B column as previously
described (Silverstein and Nachman, 1987) and were used immediately.
Foam cell formation
Thioglycolate-elicited peritoneal macrophages from background matched
control wild-type (WT), SRA2/2, TLR22/2, and CD362/2 mice were plated
on coverslips in 12-well plates in RPMI 1640 medium supplied with 10%
FCS. After 2 hr, nonadherent cells were washed out and freshmedium added
for 24 hr. Cells were then incubated with 50 mg/ml native or modified LDL
overnight in the presence or absence of various inhibitors in the samemedia.
Cells were fixed with 4% formaldehyde and stained with Oil Red O.
Binding and uptake of +NO2LDL
Peritoneal macrophages fromWT andCD362/2mice on coverslipswere pre-
treated either with SP600125, AG1879, or vehicle for 15 hr, and incubated
with DiI+NO2LDL (10 mg/ml) for 3 hr at 4
C to assess binding. To assess up-
take, cells were incubated with DiI+NO2LDL(10 mg/ml) for timed points at
37C before analysis. Nonspecific binding to free DiI was measured using
CD362/2 cells. Fluorescence intensity was examined by confocal micros-
copy (633).
Macrophage transfer experiments
Peritoneal macrophages were collected as described above from male do-
nor mice of various genotypes. Cells (12 3 106) were then injected intraper-
itoneally into each recipient apoE2/2mouse maintained on a diet containing
0.15% added cholesterol and 42%milk fat (TD88137, Harlan-Teklad) or nor-
mal chow diet for 6 weeks. Recipient mice were sacrificed after 3 days and
peritoneal macrophages collected for analysis.
Plasmids, transfections, and fusion proteins
Full-length CD36 and lyn cDNAs were cloned into pCDNA3.1 expression
plasmid (Invitrogen, Carlsbad, CA). 293T cells were transfected using Lipo-
fectAMINE (Life Technologies, Rockville, MD) according to manufacturer’s
protocol. For fusion proteins, sequences encoding the putative intracellular
carboxy-terminal domain of CD36 (MISYCACRSKTIK) or a scrambledCELL METABOLISM : SEPTEMBER 2006sequence of the same amino acids were synthesized and cloned into the
pGEX6P1 vector (Pharmacia) immediately 30 to the glutathione-S-transferase
(GST) cDNA. All clones were confirmed by direct DNA sequencing. Fusion
protein expression in transformed bacteria was induced by IPTG and then
the bacterial cells were lysed by sonication. Fusion proteins were purified
by GST affinity chromatography (GSTrap; Pharmacia) by elution with
10 mM reduced glutathione. In some experiments, the bound fusion proteins
were treated with PreScission Protease (Pharmacia) to cleave the CD36
peptide from the beads. Purified peptides or fusion proteins were dialyzed
extensively prior to use.
Purification of CD36 cytoplasmic tail binding proteins
5–10 mg of GST or GST/CD36 fusion proteins were loaded onto 5 ml of Fast
Flow glutathione sepharose cartridges (Pharmacia) and columns washed in
a minimum of 30 column volumes of PBS and 10 volumes of lysis buffer. Ly-
sates from THP-1monocytic cells were then loaded at 1ml/min, recirculating
overnight. In initial pilot experiments, cells were metabolically labeled with
200 mCi/ml 35S-methionine (Translabel, NEN) for 5 hr prior to lysis. Columns
were then washed in 30 vol lysis buffer and 10 vol 10 mM Tris-HCl (pH 7.5),
150 mM NaCl prior to elution with 10 mM glutathione. Eluted proteins were
then loaded onto a 5ml anion exchange column (Q-sepharose), washed in
10 vol of 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, and proteins were eluted
with a 0.15–1 M NaCl gradient. Fractions (0.5–1.0 ml) were analyzed by
SDS-PAGE/autoradioagraphy, silver stained 2D-gel electrophoresis or by
immunologic or kinase activity as described below.
Immunoprecipitation, immunoblot, and kinase assays
For IP studies, cells were lysed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% NP-40, 2.5 mM sodium pyrophosphate,
1 mM b-glycerophosphate, 1 mM Na3VO4, and 1 mg/ml leupeptide. The
cleared supernatant containing 500 mg protein was incubated with 3 mg of
anti-CD36 antibody immobilized on agarose beads overnight at 4C. Beads
were extensively washed, boiled in SDS-PAGE loading buffer, and the bound
material analyzed by immunoblot using antibodies for CD36, lyn, fyn, or
MEKK2. For co-IP assays, cells were treated with DSP (Dithiobis-succinimi-
dylpropionate) before harvesting in lysis buffer containing 1% CHAPS.
Lysate was immunoprecipitated using monoclonal anti-CD36 antibody and
Protein-L-Agarose. For immunoblot analysis of signaling proteins, macro-
phages were plated at 80%–95% confluency and cells were placed in
serum-free or 1% serum supplied media (RPMI 1640) for a minimum of
2 hr before treatment. Cells were then treated with modified LDL at doses
and durations indicated. Cells were then washed once in ice-cold PBS, lysed
in sample buffer, and processed as above. After chemiluminescence detec-
tion, blots were stripped and reprobed with antibodies to control proteins
(actin or nonphosphorylated MAPK) to assess loading. For in vitro kinase
assays, washed glutathione sepharose-bound proteins were incubated
in buffer containing leupeptin, aprotinin, pepstatin, PMSF, Na3VO4, 5 mM
ATP, 1 mM DTT, and 10 mCi g32P-ATP (NEN, Boston, MA) at 22C for
30 min. Reactions were stopped by the addition 12 ml 53 sample buffer at
100C and the samples then analyzed by SDS/PAGE autoradioagraphy.
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